Dr. Dana King, professor in the Department of Family Medicine, discusses a new clinical trial being conducted to determine the effect of a drug known as pioglitazone on ADMA levels, which has found to be a risk factor for heart disease among diabetes patients. He explains that pioglitazone is already an approved drug for the treatment of diabetes, and that this research is being conducted to determine what added benefits the drug may have. Dr. King provides a description of exactly how this study is conducted on the patient’s part, and the benefits associated with it.